The purpose of this study was to evaluate the effect of glycine propionyl-Lcarnitine (GPLC) supplementation and endurance training for 8 wk on aerobicand anaerobic-exercise performance in healthy men and women (age 18-44 yr). Participants were randomly assigned to 1 of 3 groups: placebo (n = 9), 1 g/d GPLC (n = 11), or 3 g/d GPLC (n = 12), in a double-blind fashion. Muscle carnitine (vastus lateralis), VO 2peak , exercise time to fatigue, anaerobic threshold, anaerobic power, and total work were measured at baseline and after an 8-wk aerobic-training program. There were no statistical differences (p > .05) between or within the 3 groups for any performance-related variable or muscle carnitine concentrations after 8 wk of supplementation and training. These results suggest that up to 3 g/d GPLC for 8 wk in conjunction with aerobic-exercise training is ineffective for increasing muscle carnitine content and has no significant effects on aerobic-or anaerobic-exercise performance.
The benefits of aerobic exercise for the cardiorespiratory system are well documented. It has been shown to increase VO 2max and aerobic endurance (American College of Sports Medicine [ACSM], 2005; Callister, Shealy, Fleck, & Dudley, 1988; Demarle et al., 2001; Fritz, 1979) in both trained and untrained populations, with the largest improvements reported for sedentary individuals because of their low initial level of fitness. Improvements in VO 2peak of 10-30% have been traditionally reported in untrained individuals (ACSM); however, the Family Heritage Study has reported changes in VO 2peak ranging from 0 to 53% after a 20-week aerobic-training program (Bouchard et al., 1999) . In addition, in populations in which low initial fitness has been noted, minor improvements in anaerobic power have been observed (Gaiga & Docherty, 1995; Rotstein, Dotan, Bar-Or, & Tenenbaum, 1986) .
The dietary nutrient L-carnitine (LC) has also been used as an aid to improve aerobic-exercise capacity (i.e., increase VO 2peak , endurance time, and free-fattyacid use), with positive findings reported in some studies using healthy individuals
The authors are with the Dept. of Health and Sport Sciences, University of Memphis, Memphis, TN 38152. (Dragan, Vasiliu, Eremia, & Georgescu, 1987; Gorostiaga, Maurer, & Echlache, 1989; Marconi, Sassi, Carpinelli, & Cerretelli, 1985; Muller, Seim, Kiess, Loster, & Richter, 2002; Vecchiet et al., 1990; Wutzke, & Lorenz, 2004) , as well as a number of studies that used patients with cardiovascular diseases (Bremer, 1983; Cacciatore et al., 1991; Campos et al., 1993; Kamikawa et al., 1984; Siliprandi, Di Lisa, & Menabo, 1990) . The mechanisms of action that might explain improvements in aerobic performance after LC supplementation have not been clearly identified but might be contingent on increasing lipid metabolism. In order for fatty acids to be metabolized they first must enter the inner mitochondrial matrix. Fatty acids by themselves cannot penetrate the membranes of the mitochondria. They must have a carrier that can penetrate both the outer and inner mitochondrial membranes. These carriers are carnitine acyl transferase enzymes, which can move freely through the membranes. There are two specific enzymes that work in this way. Carnitine acyl transferase 1 acts to convert the fatty acid to a fatty acyl carnitine that can advance through the outer membrane. Once it is through the outer membrane, carnitine transferase 2 reverses the action and reforms the fatty acid. Once the fatty acid is reformed by the carnitine transferase 2 enzyme, it can undergo beta oxidation and be used for energy production. Studies measuring substrate utilization during exercise have noted mixed results, however, with minimal increase in fatty-acid oxidation (Heinonen, 1996; Heinonen, Takala, & Kvist, 1992; Wyss, Ganzit, & Rienzi, 1990) .
More specific forms of LC, including propionyl-L-carnitine (PLC), a pharmaceutical agent used specifically to treat circulatory diseases such as peripheral artery disease, also appear to be associated with improvements in circulation and blood perfusion beyond those observed with LC supplementation alone (Brevetti, Diehm, & Lambert, 1999; Ferrari, Ceconi, Curello, Pasini, & Visioli, 1989) . Although PLC has been used with success in patients with cardiovascular-related diseases (Loffredo et al., 2007) , no investigations using healthy individuals have been conducted. Moreover, few investigations (Arenas et al., 1991 (Arenas et al., , 1994 Huertas et al., 1992; Lee, Lee, & Park, 2007) have studied the combined effect of aerobic-exercise training and LC supplementation on aerobic-exercise performance, and, in those studies, the effect of LC supplementation on aerobic-exercise performance was either not reported (Arenas et al., 1991 (Arenas et al., , 1994 Huertas et al.) or not well explained (Lee et al.) . For example, in a recent study, Lee et al. reported no improvement in VO 2max after LC supplementation but failed to report the actual data or methods of data collection for this variable.
A novel nutrient that mimics the action of PLC but also contains the amino acid glycine in a molecularly bonded form has recently been developed (glycine propionyl-L-carnitine [GPLC] ). Glycine is a precursor to carnitine biosynthesis and has been suggested to increase nitric oxide concentrations (Hafidi, Perez, & Banos, 2006) , which might positively influence physical performance. No studies, however, have investigated the effects of GPLC supplementation on muscle carnitine concentrations or exercise performance in healthy or diseased populations. Theoretically, combining GPLC with aerobic-exercise training could have an additive effect on exercise performance compared with training alone. Therefore, the purpose of this investigation was to evaluate the efficacy of GPLC and aerobic training for 8 weeks on improving aerobic-and anaerobic-exercise performance in healthy men and women.
Methods Participants
Forty-three untrained men and women between the ages of 18 and 44 years were recruited to participate in the study. Participants could not be current smokers, be using nutritional supplements, or have any cardiovascular, metabolic, or orthopedic problems that might affect their ability to perform submaximal and maximal exercise. Health history, drug and nutritional-supplement use, and physical activity questionnaires were completed by all participants to determine eligibility. Before the study, each participant was informed of all procedures and potential risks and benefits associated with the study through both verbal and written form in accordance with procedures approved by the university institutional review board for human-subjects research.
Baseline Testing
During the initial visit to the laboratory, height, weight, waist and hip circumference, and body fat (seven skinfold sites) were measured. Heart rate (HR) and blood pressure were recorded after a 10-min period of quiet rest in an isolated room, via 60-s palpation and standard auscultation procedures using a mercury manometer. Participants were familiarized with the graded exercise test (GXT) while walking on the treadmill for 4 min (2 min at each of the first two stages of the GXT) while wearing the face mask used for gas collection. They were familiarized with the anaerobic-power test by performing a similar cycle sprint test.
Graded Exercise Testing
A maximal GXT using the Bruce protocol was conducted using a motorized treadmill while expired gases were collected via face mask and analyzed (SensorMedics Vmax 229 metabolic system, Viasys Healthcare, Yorba Linda, CA) for determination of VO 2peak and anaerobic threshold, and data needed to design the individualized exercise prescriptions for study participants were obtained. The GXT was conducted in the morning (7-10 a.m.) after an overnight fast (minimum of 8 hr), and participants were asked to avoid strenuous physical tasks during the 48-hr period preceding it. In all cases, the test continued until volitional fatigue, and the highest mean 1-min averaged VO 2 value obtained during testing, used to represent VO 2peak and total exercise time (in seconds), was also recorded. The anaerobic threshold was obtained using the V-slope method (plot of CO 2 output [VCO 2 ] as a function of oxygen uptake) as described by Beaver, Wasserman, and Whipp (1986) , using software available with the metabolic system. Data were filtered and analyzed by the same investigator for all tests.
During the GXT, HR was continuously monitored via electrocardiograph tracings (SensorMedics Max-1 ECG unit, Viasys Healthcare, Yorba Linda, CA), and expired gas was continuously monitored via breath-by-breath samples to determine VO 2 and respiratory-exchange ratio. Blood pressure was monitored at rest and during testing, and the Borg rating of perceived exertion was used by the participants to indicate their level of perceived effort. Specifically, data on HR, respiratory-exchange ratio, and rating of perceived exertion were recorded at the end of each 3-min stage of the GXT for comparison between pre-and postintervention and between groups. The resting HR and blood-pressure values before the GXT were used for comparisons between pre-and postintervention. After the test, participants were allowed a passive cool-down until their HR fell below 120 beats/min or stabilized.
Anaerobic-Power Testing
On a separate day from the GXT, participants completed a 30-s test of anaerobic power on a Lode Excalibur Sport cycle ergometer (Lode B.V. Medical Technology, Groningen, The Netherlands) interfaced with a computer. The force (N) that participants pedaled against was determined based on their lean body mass and equal to lean body mass (kg) × 0.7. Before performing the 30-s sprint, participants underwent a 5-min warm-up using a low intensity (75 W), in which they performed a 3-to 5-s sprint at the top of each minute to familiarize themselves with the protocol. The peak and mean power relative to lean body mass, fatigue rate, and total work relative to lean body mass were recorded. All testing (including aerobic-exercise training) was supervised by a clinical exercise physiologist, and all procedures were performed in accordance with the established guidelines of the ACSM. Using the same procedures described here for each test, these same variables were measured after the 8-week intervention.
Supplementation
After the conclusion of all preintervention tests, participants were provided with study instructions and were randomized in a double-blind manner to one of the following three conditions plus aerobic exercise: 1 g cellulose (placebo, n = 9), 348 mg glycine + PLC at 1 g/day (GPLC-1, n = 11), or 1,044 mg glycine + PLC at 3 g/day (GPLC-3, n = 12). Capsules were provided to participants in unlabeled bottles every 2 weeks and were identical in appearance. In all conditions participants ingested three capsules twice daily (morning and evening) to allow for the described dosages. The GPLC consisted of a molecularly bonded form of PLC and the amino acid glycine (GlycoCarn, Sigma-tau HealthScience S.p.A, Rome, Italy). This is a USP-grade nutritional supplement. The actual dose of PLC was provided at either 1 or 3 g/day (~166 or 500 mg PLC per capsule, respectively), whereas the glycine content was equal to 348 mg in the 1-g/day treatment and 1,044 mg in the 3-g/day treatment. For ease of reporting throughout this article, we refer to the two dosages as simply 1 and 3 g/day to reference the actual PLC content. After randomization all participants began the aerobic-exercise program.
Aerobic-Exercise Training
All participants performed 8 weeks of supervised aerobic exercise consisting of stationary cycling and walking/jogging (on an outdoor track or indoor treadmill). The training intensity and duration began at the lower limit of the ACSM recommendations (55-60% HR reserve for 30 min) and progressed to higher levels over the 8-week period (to 75-85% HR reserve for 45 min; Week 1 = 55-65%, Week 2 = 65-75%, Week 3 = 70-80%, and Weeks 4-8 = 75-85%). The training intensity was prescribed in the form of a "target" HR range. HR (via Polar monitors) and rating of perceived exertion were recorded at three equally spaced times during each exercise session to ensure that participants were training at the appropriate intensity, and all exercise logs were maintained by research assistants.
Muscle Biopsies
In a subset of the participant population (n = 18, 6 participants from each group), a biopsy of the vastus lateralis muscle was taken before and after all testing was completed, as previously described (Schilling, Fry, Chiu, & Weiss, 2005) . Tissue samples (~30-40 mg) were quick-frozen in isopentane cooled in liquid nitrogen and immediately stored at -80 °C. Samples were assayed for total, free, and acyl carnitine (combined short-and long-chain acyl carnitines) using ion-exchange/ reversed-phase HPLC. This procedure has four distinct phases. The first phase involves isolating carnitine and acyl carnitines by protein precipitation/desalting and silica-gel cation exchange. The second phase involves derivatization of carnitine and acyl carnitines with the reagent pentafluorophenacyl trifluoromethane-sulfonate. The third phase consists of sequential ion-exchange/reversed-phase chromatography of carnitine and acyl carnitine esters. After this, carnitine is detected by mass spectrometry and tandem mass spectrometry. This multicomponent protocol has been previously described in detail by Minkler, Ingalls, and Hoppel (2005) .
Dietary Records
All participants were instructed to maintain their normal diets during the study period. Participants completed 7-day food records at Week 1 and Week 8 of the intervention and were given specific instructions regarding how to record portion sizes and quantities, in addition to viewing food models to enhance precision. Records were analyzed for total kilocalories, protein, carbohydrate, fat, and vitamins C, E, and A using Diet Analysis Plus (ESHA Research, Salem, OR).
Statistical Analysis
Differences between and within groups were analyzed via a 3 (group) × 2 (session-pre-and postintervention) mixed factorial analysis of variance (ANOVA) using SPSS statistical software (v. 14.0, SPSS, Chicago). When appropriate, significant interactions (p ≤ 0.05) and main effects were further analyzed using Tukey's post hoc tests. Effect-size calculations were performed using Cohen's d, and all descriptive data are presented as M ± SD.
Results
Of the 43 participants who were enrolled in the program, only 32 successfully completed all aspects of the program and were therefore included in the statistical analysis (placebo group = 4 men, 5 women; GPLC-1 = 5 men, 6 women; and GPLC-3 = 0 men, 12 women). The other 11 participants voluntarily withdrew (n = 8) or failed to complete the entire program (n = 3).
Compliance
Supplement compliance was measured every 2 weeks via capsule counts on bottle return and was greater than 95% in all three groups, with no statistical difference between groups. No adverse side effects of supplementation were reported by participants. There were no statistical differences between groups for percentage of exercise sessions completed (placebo 84.3% ± 9.4%, GPLC-1 90.8% ± 7.5%, and GPLC-3 88.8% ± 10.3%) or percentage of target HR obtained during exercise (placebo 91.3% ± 12.6%, GPLC-1 93.9% ± 7.6%, and GPLC-3 90.5% ± 17.9%).
Descriptive and Dietary Variables
No statistical interaction (p ≤ .05) effect or main effect was noted for age, height, weight, body-fat percentage, body-mass index, waist-to-hip ratio, resting HR, resting systolic blood pressure, or resting diastolic blood pressure (Table 1 ). In addition, no interaction effect or main effects were noted for total kilocalories, total grams of protein, percentage of protein, total carbohydrate, percentage of carbohydrate, total fat, percentage of fat, or vitamin C, vitamin E, and vitamin A intake (Table 2) . Treatment main effects were noted for vitamin E intake (p = .027), with the placebo group having lower vitamin E intake than the GPLC-1 at baseline (Table 2) .
Muscle Carnitine and Performance Variables
No significant interaction or main effects were observed for total muscle carnitine, free muscle carnitine, or acyl carnitine concentrations from pre-to postsupplementation (Table 3) . The results for exercise performance also showed no significant interactions or main effects for absolute or change values for VO 2peak or total exercise time during the GXT. The percent changes in VO 2peak and time to exhaustion during the GXT were 5.1% (placebo), 9.4% (GPLC-1), and 6.5% (GPLC-3) and 1.0% (placebo), 4.3% (GPLC-1), and 0.91% (GPLC-3), respectively (p ≤ .05; Table 4) .
No interaction or main effect for time was found for anaerobic threshold. There was, however, a significant (p = .036) treatment main effect for anaerobic threshold, with GPLC-1 demonstrating a higher anaerobic threshold (64.5% ± 8.2%) than the placebo group (56.0% ± 7.4%). In addition, the difference in percent change for anaerobic threshold from pre-to postintervention between the placebo group (3.5%) and the two GPLC groups (GPLC-1 = 10.3% and GPLC-3 = 8.8%) was not statistically significant but approached significance (p = .09; Table 4) .
Values for HR, respiratory-exchange ratio, and rating of perceived exertion collected at the end of the first three stages of the GXT were generally lower for all groups postintervention than preintervention. There were no statistically significant differences, however, within or between groups (p > .05) during any stage of the GXT (Table 5) .
No significant interaction or main effects were noted within or between groups for total work, peak power, or mean power when expressed as absolute values or relative to lean body mass (p > .05). In addition, there were no significant differences in percent change from pre-to postintervention for total work, peak power, and mean power between groups (Table 4) .
Calculations for effect size from pre-to postintervention for all performancerelated variables are presented in Table 6 . The effect sizes were small with the 81.7 ± 60.9
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Discussion
The findings of the current investigation indicate that 1 or 3 g/day of GPLC supplementation for 8 weeks in combination with aerobic training does not improve aerobic-or anaerobic-exercise performance variables more than aerobic exercise alone. There was excellent, and similar, compliance to supplementation between groups, as well as similar compliance to aerobic training. Thus, we do not believe that our lack of finding for a benefit of GPLC is the result of poor supplement or training compliance. Dietary records were also similar between all three groups over time, with the exception of a slightly greater vitamin E intake in the GPLC-1 group than in the placebo group. Nonetheless, the difference in vitamin E intake is so small that it likely had no influence on the results, because previous literature suggests that vitamin E does not improve exercise performance, even with a supplemented dosage of 100-200 mg daily (Dunford, 2006) . The aerobic-performance variables including VO 2peak and time to exhaustion have been shown to improve with aerobic training (ACSM, 2005; Bouchard et al., 1999) and with carnitine supplementation (Dragan et al., 1987; Marconi et al., 1985; Vecchiet et al., 1990) independently. The training protocol used in the current investigation did result in a modest, albeit nonsignificant, improvement in VO 2peak and time to exhaustion, which was similar in all three groups and indicates that GPLC offers no additional benefit for improving exercise performance above aerobic training alone in healthy individuals. The traditional reported values of VO 2peak improvements from aerobic training alone are 10-30% (ACSM). The Family Heritage Study, however, has noted changes in VO 2peak ranging from 0 to 53% after a 20-week aerobic training program (Bouchard et al.) . Based on these observations, our observed increases in VO 2peak appear normal, although falling in the lower end of the range.
Our finding of no statistically significant increases in aerobic performance with GPLC supplementation is somewhat unexpected and is contradictory to the find- ings of other studies that examined the effect of LC in healthy adults. For example, Vecchiet et al. (1990) used 2 weeks of oral LC supplementation at a dose of 2 g/day in 10 moderately trained young men and reported a 6.9% improvement in VO 2max above that observed for placebo. Marconi et al. (1985) noted similar findings (6.0% increase) for VO 2max in competitive long-distance walkers provided 4 g/day of LC for 2 weeks. In addition, Dragan et al. (1987) reported a predicted increase in VO 2max after intravenous LC supplementation of 3 g/day in elite athletes. Not all the studies that have examined the effect of LC supplementation on exercise performance have reported significant findings, however. Colombani et al. (1996) reported no change in well-trained endurance athletes' marathon run time (or predicted VO 2max ) when participants received 2 g of LC 2 hr before the race. Wyss et al. (1990) noted no change in aerobic performance in healthy men as measured by VO 2max and exercise endurance after the administration of 1 g/day of LC for 7 days. In two separate but related studies, Greig et al. (1987) and Onyono-Enguelle et al. (1988) showed no changes in VO 2max after supplementation of 2 g/day of LC for 28 days.
The findings of the cited studies (Colombani et al., 1996; Greig et al., 1987; Onyono-Enguelle et al., 1988; Wyss et al., 1990) are in agreement with those of the current study. To our knowledge this is the first study to use healthy participants to examine the effect of GPLC supplementation for up to 8 weeks in combination with an aerobic-exercise training program. Although some previous studies demonstrated an improvement in VO 2max after LC supplementation (Dragan et al., 1987; Marconi et al., 1985; Vecchiet et al., 1990) , the overall percent changes in VO 2max were similar to those found in the current study. Because of the higher variability among our participants, however, group differences were not detected. Perhaps a more homogeneous sample of participants would be needed in future studies to maximize the ability to detect differences across time and between groups. Related to this, previous studies demonstrating an improvement in exercise performance using older, diseased participants likely report such findings based on the very low level of physical conditioning of these participants at study entry. Aside from the need to maintain a homogeneous sample, future studies should strive to include larger sample sizes than have been used in previous work, including the current study. Small sample sizes paired with high variability results in nonsignificant findings. Further research using these suggestions might provide additional insight into the efficacy of various forms of LC in improving exercise performance.
With regard to exercise time to exhaustion, it is possible that a longer duration exercise or a time trial at a submaximal workload would better detect the potential benefits of GPLC, because longer duration bouts might function to deplete muscle glycogen stores and result in greater reliance on fatty acids for energy production. Because carnitine is an intermediate in lipid metabolism and has been suggested to be the rate-limiting step in this process (Bremer, 1983; Fritz, 1979) , increased availability of carnitine might allow for greater fat utilization during longer duration exercise bouts. Further research on the role of carnitine and the limiting steps of lipid utilization is needed to address this proposed hypothesis. In addition, the type of carnitine might have an impact, with PLC being considered the most specific to skeletal muscle, potentially leading to a greater influence on lipid metabolism.
There was no statistically significant effect for anaerobic threshold, although moderate effect sizes were noted for the GPLC-1 (d = 0.58) and groups (Table 6) . No previous study to our knowledge has reported on anaerobic threshold after LC supplementation. At least two previous studies (Gorostiaga et al., 1989; Oyono-Enguelle et al., 1988) , however, have reported mixed findings in response to aerobic-exercise training and carnitine supplementation with regard to substrate utilization. Oyono-Enguelle et al., using 10 untrained men given 2 g/day of LC orally for 28 days, reported no change in respiratory-exchange ratio after or during a GXT. Participants were measured during fixed-workload exercise for 60 min followed by 120 min of rest on the 10th, 20th, and 28th day of supplementation and again between the 72nd and 86th day from the start of supplementation. Gorostiaga et al. had 10 participants perform 45 min of cycling at 66% of VO 2max after 2 g/day of oral LC for 28 days and reported a significant decrease in respiratory-exchange ratio, suggestive of greater fatty-acid utilization. Although carnitine is necessary for oxidation of fatty acids, and LC might decrease the use of carbohydrate metabolism during exercise with greater reliance on lipids, we failed to note any difference in either respiratory-exchange ratio (Table 5) or anaerobic threshold. Based on our effect-size calculations, however, it is possible that we were underpowered to detect statistical significance in anaerobic threshold. Future studies using larger sample sizes might be needed to further evaluate the role of GPLC in increasing the anaerobic threshold in otherwise healthy individuals.
Although there were no statistically significant improvements in anaerobic performance, all three groups showed modest improvements in peak power, mean power, and total work (Table 4) . These findings support those of Trappe, Costill, Goodpaster, Vukovich, and Fink (1994) , who reported no further improvement in anaerobic work (five 100-yd sprints with 2-min rest intervals in an Olympic size pool) after supplementation of 2 g/day of oral LC for 7 days in college swimmers. In further agreement, Ransone and Lefavi (1997) provided supplementation of 2 g/day of oral LC for 21 days and noted no effect on anaerobic performance in elite runners after a high-intensity run/sprint protocol. In contrast, other studies using patients with mitochondrial myopathies (Campos et al., 1993) and peripheral artery disease (Colombani et al., 1996) have reported significant increases in muscle strength after LC supplementation for up to 11 months. Therefore, carnitine might be more effective at increasing muscle strength and other indices of anaerobicexercise performance in diseased populations than in healthy adults.
Although not including measures of anaerobic-exercise performance directly, data from Kraemer et al. (2006) and Volek et al. (2002) indicate positive hormonal adaptations and decreased markers of exercise stress, respectively, after 2 g/day of oral LC supplementation for 3 weeks. These data are in reference to young, otherwise healthy men. They indicate that it is possible that carnitine supplementation favorably affects variables not measured in the current investigation. Future studies are needed to confirm the findings of Kraemer et al. and Volek et al. In addition, the muscle carnitine concentrations did not improve significantly (Table 3) . Although both the placebo and GPLC-1 groups experienced a decrease in muscle carnitine from pre-to postintervention, a finding that has previously been observed after intense aerobic training (Arenas et al., 1991 (Arenas et al., , 1994 Huertas et al., 1992; Lee et al., 2007) , total carnitine was decreased to a lesser degree with GPLC-3, and acyl carnitine was increased but in a nonsignificant manner. These findings have also been previously observed in studies (Arenas et al., 1991 (Arenas et al., , 1994 Huertas et al.; Lee et al.) in which participants received carnitine in doses from 1 (Arenas et al., 1991) to 4 (Lee et al.) g/day for periods of 4 weeks to 6 months. Not all studies have shown increases in muscle carnitine after LC supplementation. In very similar protocols, researchers found no significant increase in muscle carnitine after either 14 days (Barnett et al., 1994) or 3 months (Watcher et al., 2002) of supplementation with 4 g/day in healthy men. Recent work by Stephens, Constantin-Teodosiu, Laithwaite, Simpson, and Greenhaff (2006) demonstrates that insulin can augment skeletal-muscle carnitine transport, leading to increased muscle-tissue carnitine content. In addition, an acute state of hyperinsulinemia induced via high-carbohydrate feeding, in conjunction with carnitine supplementation to induce hypercarnitinemia, might promote more favorable retention of carnitine in skeletal muscle (Stephens, Evans, Constantin-Teodosiu, & Greenhaff, 2007) . Although it seems reasonable to hypothesize that increased carnitine tissue content might lead to greater energy production via fatty-acid metabolism and, hence, improved exercise performance, the supplementation protocol used here did not increase muscle carnitine concentrations. Without a significant increase in muscle carnitine content, it follows that other dependent measures might not be favorably affected. Based on the recent findings of Stephens (2006 Stephens ( , 2007 , future studies might consider carnitine administration along with carbohydrate-rich feedings to induce hyperinsulinemia in an attempt to increase skeletal-muscle carnitine content.
Some potential limitations of the current research need to be presented. First, the precision of maximal exercise testing using the GXT with gas collection might not be adequate to assess small changes in aerobic performance. Hence, although participants might have improved their aerobic capacity, our testing methods might not have been able to detect small differences. This is especially true considering the potential learning curve involved with maximal stress testing when collecting expired gases. We attempted to control for this by allowing all participants a familiarization trial before they performed the GXT. Nonetheless, this familiarization trial was not a complete GXT, and perhaps that would have been most appropriate. In relation to this, individual response to training interventions is also an issue, and we made every attempt to address this by providing consistent interaction with all participants throughout the training period.
Second, we noted a high degree of variability in participants' response to the intervention. This, coupled with our relatively small sample size, decreased our statistical power and might have made it difficult to observe group differences. A final limitation associated with our work is the lack of gender matching among the groups. This is in part because of gender differences in drop-out or withdrawal. That is, each group started with approximately one third men and two thirds women. Unfortunately, by chance alone we lost 4 men from the GPLC-3 group and ended up with no men in that condition. Although we do not believe that the unequal gender balance significantly influenced the results, we do concede that there might be gender differences in response to aerobic training (Tarnopolsky, 2000) . We performed further analysis, however, to investigate the influence of gender on our dependent variables and noted no statistical differences between genders for any variable (Gender × Time). If focused on healthy participants, future studies using larger, more homogeneous samples, possibly including longer duration exercise tests as dependent variables, are necessary to gain a better understanding of the effect of GPLC on aerobic-and anaerobic-exercise performance.
To our knowledge, the current investigation is the first to use a combination of LC supplementation, in the form of GPLC, and aerobic exercise in an attempt to improve markers of exercise performance. Supplementation was well tolerated by all participants, with no reports of adverse side effects during the 8-week intervention period. We noted no additional benefits of GPLC beyond aerobic exercise alone, however, in improving any measure of aerobic-or anaerobic-exercise performance or muscle carnitine concentrations. Our data are in reference to a sample of younger, healthy participants. Future studies might use metabolically or cardiovascularly compromised participants, populations that likely are more responsive to carnitine supplementation.
